According to Stratistics MRC, the Global Artemisinin Combination Therapy Market is accounted for $473.24 million in 2020 and is expected to reach $1,051.92 million by 2028 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are major factors driving the growth of the market. However, limited number of manufacturers globally is hampering the market.
Request for a Free Sample Copy of Report at www.strategymrc.com/report/artemisinin-combination-therapy-market/request-sample
By type, Artesunate–Mefloquine segment is experiencing considerable market growth, due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.
Based on the geography, Middle East & Africa is dominating the market during the forecast period, owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.
Some of the key players profiled in the Artemisinin Combination Therapy Market include Cipla Ltd., Desano Inc., Hovid Berhad, KPC Pharmaceuticals, Guilin Pharmaceutical (Fosun Pharmaceutical ), Novartis AG, Sanofi S.A.
Types Covered:
• Artemether+Lumefantrine
• Artesunate+Amodiaquine
• Artesunate+Mefloquine
• Artesunate+Sulfadoxine-Pyrimethamine
• Dihydroartemisinin+Piperaquine
• Pyronaridine-Artesunate
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
If Any Query? Ask Our Industry Expert at www.strategymrc.com/report/artemisinin-combination-therapy-market/request-customization
Explore the list of attractive markets during this time of Pandemic @ www.strategymrc.com/covid-19-impact-reports
About Us:
StrategyMRC research reports and publications are routed to help clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. We track 30+ industries and cover 800 market segments.
Contact Us:
Stratistics Market Research Consulting
Phone: +1-301-202-5929
Email: info@strategymrc.com
Website: www.strategymrc.com/
Twitter:twitter.com/StratisticsMRC
LinkedIn: www.linkedin.com/company/stratistics-market-research-consulting-pvt-ltd?trk=mini-profile